JUN 0 4 2007 W

/6 // I Intarcia Ref. No. INT 004.10 USSN 10/004,118 PATENT

#### CERTIFICATE OF FIRST CLASS MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Gary R. Fabian

Printed Name

Gary R. Fabian

30 May 2007

Signature

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE				
In Re Application of: Stanford Mark Moran	Confirmation No. 8022			
Serial No.: 10/004,118	Art Unit: 1647			
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.			
Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON				

## **TRANSMITTAL**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

- 1. Transmittal;
- 2. Modified Form 1449 and copies of three cited references;
- 3. Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97;
- 4. Certificates of First Class Mailing; and
- 5. Return Receipt Postcard.

## Authorization to Charge Deposit Account.

No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 30 May 2007

By

Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicant

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608



CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

	Gary R. Fabian		
Printed Name	Gory of Fabrain	30 May 2007	
Signature		Date of Deposit	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE						
In Re Application of: Stanford Mark Moran Confirmation No. 8022						
Serial No.: 10/004,118	Art Unit: 1647					
Filing Date: 30 October 2001 Examiner: Seharaseyon, J.						
Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON						

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copies of the cited references accompany this paper.

Further, because this application was filed after 30 June 2003, copies of the cited U.S. Patent publication has not been submitted pursuant to the waiver described in pre-OG Notice "Information Disclosure Statements may be filed without copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record in the present application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to

the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

### **Authorization to Charge Deposit Account:**

**No fee is believed due** because this Supplemental Information Disclosure Statement is filed before the mailing of a first Office action after the filing of a request for continued examination under § 1.114 (see, 37 C.F.R. 1.97(b)(4)).

However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** (please reference docket number **INT 004.10**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Date: 30 May 2007

y: Jay 10

Agent for Applicant

Registration No. 33,875

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608 Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

# FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Sheet 1 of 1

In the Application of: Stanford Mark Moran

n

Confirmation No.: 8022

Serial No.: 10/004,118

Art Unit: 1647

Filed: 30 October 2001

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended -- METHOD FOR

TREATING DISEASES WITH OMEGA INTERFERON --

	U.S. PATENT DOCUMENTS						
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	EA-						

FOREIGN PATENT DOCUMENTS								
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Trans YES	ation NO
	EB-							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
Exam. Init. Ref. Desig. Description					
	EC-01	ZHENG et S. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis" Beijing Medical Journal 13(2):80-81 (1998). WITH ACCOMPANYING ENGLISH TRANSLATION.			
	EC-02	ZHANG et at. "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis" Journal of Clinical Pediatrics 14(2):83-84 (1996). WITH ACCOMPANYING ENGLISH TRANSLATION.			
	EC-03	ZHANG et al. "Efficacy Observations of Different Dosages of Interferon to Treat 150 Hepatitis B Carriers" Current Physician 2(12):45-46 (1997). WITH ACCOMPANYING ENGLISH TRANSLATION.			

Examiner:	 _Date Considered:	

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.